Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees

Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.